AN
ANGO.US AngioDynamics Inc
- Market cap
- USD 499M
- P/E
- -
- P/B
- 3.07x
- ROE
- -17.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Aug 2026.
Is ANGO.US undervalued?
Graham numberThe Graham number of AngioDynamics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AngioDynamics Inc fundamental analysis
No fundamental analysis for AngioDynamics Inc yet.
AngioDynamics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AngioDynamics Inc
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally. The company operates through Med Tech and Med Device segments. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVa…
Full company profileAngioDynamics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Aug 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
AngioDynamics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 350M | 344M | 359M | 264M | 291M | 316M | 339M | 304M | 292M | 320M | 324M |
| Gross Profit | 144M | 144M | 156M | 150M | 157M | 166M | 174M | 155M | 158M | 175M | 192M |
| Operating Income | -11.2M | -14.2M | -9.40M | -167M | -35.3M | -28.5M | -51.2M | -192M | -40.0M | -39.9M | -29.2M |
| EBITDA | 13.4M | 8.96M | 16.3M | -143M | -9.28M | 11.1M | 12.2M | -6.13M | 1.74M | 488K | -6.84M |
| Net Income | -7.05M | 16.3M | 61.3M | -167M | -31.5M | -26.5M | -52.4M | -184M | -34.0M | -36.7M | -28.4M |
| EPS | -0.19 | 0.44 | 1.64 | -4.39 | -0.82 | -0.68 | -1.33 | -4.59 | -0.83 | -0.88 | -0.68 |
| Balance Sheet | |||||||||||
| Total Assets | 708M | 705M | 836M | 596M | 561M | 553M | 533M | 318M | 280M | 267M | 242M |
| Total Liabilities | 191M | 163M | 222M | 140M | 122M | 128M | 154M | 112M | 97.2M | 96.3M | 78.0M |
| Shareholders' Equity | 517M | 543M | 615M | 456M | 439M | 424M | 378M | 206M | 183M | 171M | 164M |
| Cash & Short-term Investments | 48.8M | 75.4M | 228M | 54.4M | 48.2M | 28.8M | 44.6M | 76.1M | 55.9M | 53.9M | 34.0M |
| Total Debt | 106M | 93.7M | 137M | 40.8M | 22.4M | 33.8M | 64.6M | 4.73M | 10.1M | - | 10.7M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 55.7M | 41.3M | 37.4M | -14.6M | 24.1M | -7.19M | 78.0K | -28.2M | -10.1M | 3.09M | -61.3M |
| Capital Expenditure | 3.00M | 3.66M | 3.12M | 7.59M | 5.19M | 4.30M | 4.35M | 5.77M | 4.46M | 2.58M | 1.52M |
| Free Cash Flow | 52.7M | 37.6M | 34.3M | -22.1M | 18.9M | -11.5M | -4.27M | -33.9M | -14.6M | 508K | -62.8M |
| Ratios | |||||||||||
| ROE | -1.4% | 3.0% | 10.0% | -36.6% | -7.2% | -6.3% | -13.9% | -89.7% | -18.6% | -21.5% | -17.3% |
| ROA | -1.0% | 2.3% | 7.3% | -28.0% | -5.6% | -4.8% | -9.8% | -58.0% | -12.1% | -13.8% | -11.7% |
| Net Profit Margin | -2.0% | 4.7% | 17.1% | -63.1% | -10.8% | -8.4% | -15.5% | -60.7% | -11.6% | -11.5% | -8.8% |
| Debt to Equity | 0.20x | 0.17x | 0.22x | 0.09x | 0.05x | 0.08x | 0.17x | 0.02x | 0.06x | - | 0.07x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
AngioDynamics Inc dividends
AngioDynamics Inc has not paid dividends in the last 9 fiscal years.
Who owns AngioDynamics Inc
- Insiders 13.27%
- Institutions 86.73%
- Public & others 0.00%
- Shares outstanding 42.1M
- Free float 32.8M
Top funds holding ANGO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.25M | 2.97% | +6.30% | Sep 2026 |
| iShares Russell 2000 ETF | 935K | 2.22% | 0.00% | Oct 2026 |
| Royce Small-Cap Opportunity Invmt | 708K | 1.68% | +0.12% | Sep 2026 |
| FTGF RY US SmCp Opp A USD Dis(A) | 642K | 1.53% | -10.60% | Sep 2026 |
| CREF Total Global Stock Account R3 | 426K | 1.01% | -31.97% | Aug 2026 |
| Fidelity Small Cap Index | 407K | 0.97% | 0.00% | Aug 2026 |
| Nuveen Quant Small Cap Equity R6 | 382K | 0.91% | 0.00% | Aug 2026 |
| Royce Micro-Cap Trust | 326K | 0.78% | +14.97% | Sep 2026 |
| First Eagle Small Cap Opportunity I | 311K | 0.74% | 0.00% | Sep 2026 |
| SEB Nordamerikafond Småbolag | 291K | 0.69% | -3.60% | Sep 2026 |
| iShares Russell 2000 Value ETF | 270K | 0.64% | 0.00% | Oct 2026 |
| BlackRock Advantage Small Cap Core Instl | 241K | 0.57% | +4.61% | Sep 2026 |
| Vanguard Russell 2000 ETF | 216K | 0.51% | +1.08% | Sep 2026 |
| Segall Bryant & Hamill Sm Cp Val Ins | 205K | 0.49% | 0.00% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 197K | 0.47% | +0.23% | Oct 2026 |
| DFA U.S. Small Cap I | 184K | 0.44% | 0.00% | Sep 2026 |
| iShares US Medical Devices ETF | 178K | 0.42% | -1.12% | Oct 2026 |
| Fidelity Extended Market Index | 175K | 0.42% | -15.15% | Sep 2026 |
| Royce Micro-Cap Invmt | 161K | 0.38% | +14.87% | Sep 2026 |
| DFA US Micro Cap I | 144K | 0.34% | 0.00% | Sep 2026 |
Top institutions holding ANGO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 3.80M | 9.04% | +3.18% | Jun 2026 |
| Point72 Asset Management, L.P. | 3.06M | 7.28% | -3.75% | Jun 2026 |
| Systematic Financial Management LP | 2.64M | 6.28% | +7.60% | Jun 2026 |
| Armistice Capital, LLC | 2.20M | 5.23% | +17.60% | Jun 2026 |
| Royce & Associates, LP | 1.97M | 4.68% | +28.84% | Jun 2026 |
| Broadfin Holdings LLC | 1.82M | 4.32% | -12.12% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.69M | 4.03% | -1.86% | Jun 2026 |
| Weber Capital Management LLC | 1.35M | 3.21% | -0.49% | Sep 2026 |
| Nuveen, LLC | 1.20M | 2.85% | -1.38% | Jun 2026 |
| Geode Capital Management, LLC | 1.02M | 2.43% | +3.58% | Jun 2026 |
| State Street Corp | 958K | 2.28% | -28.17% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 949K | 2.26% | -2.08% | Sep 2026 |
| Segall Bryant & Hamill | 927K | 2.20% | -4.06% | Jun 2026 |
| Bastion Asset Management Inc. | 923K | 2.20% | -29.68% | Jun 2026 |
| Pier Capital, LLC | 807K | 1.92% | +1.25% | Jun 2026 |
| Millennium Management LLC | 783K | 1.86% | +21.48% | Jun 2026 |
| Renaissance Technologies Corp | 734K | 1.75% | -8.64% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 693K | 1.65% | -8.69% | Jun 2026 |
| Paradigm Capital Management, Inc. | 671K | 1.60% | -6.54% | Jun 2026 |
| AQR Capital Management LLC | 589K | 1.40% | +134.24% | Jun 2026 |
AngioDynamics Inc company profile
- Company name
- AngioDynamics Inc
- Ticker
- ANGO.US
- Exchange
- USA Stocks
- Listed since
- May 27, 2004
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 632
- Fiscal year end
- May
- Address
- 14 Plaza Drive, Latham, NY, United States, 12110
- Phone
- 518 795 1400
- Website
- angiodynamics.com
About AngioDynamics Inc
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally. The company operates through Med Tech and Med Device segments. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers' off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage. It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which include angiographic catheters, guidewires, drainage catheters, and micropuncture kits for use in invasive procedures. In addition, the company provides total abscession drainage catheters for multi-purpose/general and biliary configurations, and nephrostomy options; mini stick MAX Coaxial microintroducer kits and micro-introducer kits; ports; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.
AngioDynamics Inc management
10- Mr. Stephen A. TrowbridgeExecutive VP & CFO · born 1974
- Mr. Lawrence T. WeissSenior VP, Chief Legal Officer & Corporate Secretary · born 1970
- Mr. Warren G. NighanSenior Vice President of Regulatory Affairs, Quality & Global Supply Chain · born 1969
- Ms. Laura PiccininiSenior VP and GM of Cardiovascular & International · born 1969
- Mr. Eric HonrothPresident, CEO & Director · born 1971
- Mr. Saleem M. CheeksVice President of Communications
- Mr. Benjamin H. DavisSenior Vice President of Business Development & Strategy · born 1964
- Ms. Marna I. Bronfen-MooreSenior Vice President of Human Resources · born 1967
- Mr. Chad T. CampbellSenior VP and GM of Oncology & Interventional Devices · born 1971
- Ms. Kim L. SeaburySenior Vice President of Information Technology · born 1967